Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation

Ramos, Marcelo Cristiano de Azevedo; Folgueira, Maria Aparecida Azevedo Koike; Maistro, Simone; Campolina, Alessandro Gonçalves; Soárez, Patricia Coelho de; Bock, Geertruida Hendrika de; Novaes, Hillegonda Maria Dutilh; Diz, Maria Del Pilar Estevez.
Rev. saúde pública (Online) ; 52: 94, 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-979019

Documentos relacionados

  1. The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in <i>BRCA1</i> and <i>BRCA2</i>.
  2. Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops.
  3. Tumor-reactive antibodies evolve from non-binding and autoreactive precursors.
  4. BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
  5. Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
  6. Cost-effectiveness of Ovarian Cancer Prevention Strategies.
  7. Five-year survival decreases over time in patients with BRCA-mutated ovarian cancer: a systemic review and meta-analysis.
  8. Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
  9. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.
  10. Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.